Oliver de Giorgio-Miller, chairman of ValiRx Plc's (LON:VAL), tells Proactive Investors that their two lead cancer compounds are at stages in their development that they offer potential investors an investable proposition and an attractive offering to joint venture partners.
They've been given the green light to now expand the scope of the study around VAL201 - escalating the dosage with patients currently being recruited.
Meet360 Blockchain Inc at our event,New York, 18 April 2018.Register here >>